دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Racism in the USA: ensuring Asian American health equity
The Lancet
doi : 10.1016/S0140-6736(21)00769-8
EDITORIAL| VOLUME 397, ISSUE 10281, P1237, APRIL 03, 2021
Africa needs local solutions to face the COVID-19 pandemic
Yap Boum,Lisa M Bebell,Anne-Cécile Zoung-Kanyi Bisseck
doi : 10.1016/S0140-6736(21)00719-4
COMMENT| VOLUME 397, ISSUE 10281, P1238-1240, APRIL 03, 2021
ART in pregnant women living with HIV
Yvonne Gilleece,Dagny Krankowska
doi : 10.1016/S0140-6736(21)00626-7
no discription
Wait and see for acute dialysis: but for how long?
Marlies Ostermann,Nuttha Lumlertgul
doi : 10.1016/S0140-6736(21)00466-9
COMMENT| VOLUME 397, ISSUE 10281, P1241-1243, APRIL 03, 2021
Migration and health in Latin America during the COVID-19 pandemic and beyond
Ietza Bojorquez,B?ltica Cabieses,Carlos Ar?squipa,Juan Arroyo,Andrés Cubillos Novella,Michael Knipper,Miriam Orcutt,Ana Cristina Sedas,Karol Rojas
doi : 10.1016/S0140-6736(21)00629-2
COMMENT| VOLUME 397, ISSUE 10281, P1243-1245, APRIL 03, 2021
10 years of the Syrian conflict: a time to act and not merely to remember
Samer Jabbour,Jennifer Leaning,Iman Nuwayhid,Alastair Ager,Melani Cammett,Omar Dewachi,Fouad M Fouad,Rita Giacaman,Debarati Guha Sapir,Ghassan Hage,Ziad Majed,Rabie Nasser,Annie Sparrow,Paul Spiegel,Ahmad Tarakji,Sarah Leah Whitson,Nasser Yassin
doi : 10.1016/S0140-6736(21)00623-1
COMMENT| VOLUME 397, ISSUE 10281, P1245-1248, APRIL 03, 2021
The need to prioritise childhood tuberculosis case detection
Esin Nkereuwem,Beate Kampmann,Toyin Togun
doi : 10.1016/S0140-6736(21)00672-3
COMMENT| VOLUME 397, ISSUE 10281, P1248-1249, APRIL 03, 2021
New Libyan Government faces health challenges
Sharmila Devi
doi : 10.1016/S0140-6736(21)00770-4
WORLD REPORT| VOLUME 397, ISSUE 10281, P1250, APRIL 03, 2021
UK launches new health security agency
Jacqui Thornton
doi : 10.1016/S0140-6736(21)00771-6
WORLD REPORT| VOLUME 397, ISSUE 10281, P1251, APRIL 03, 2021
New EU health programme comes into force
Udani Samarasekera
doi : 10.1016/S0140-6736(21)00772-8
WORLD REPORT| VOLUME 397, ISSUE 10281, P1252-1253, APRIL 03, 2021
AI-facilitated health care requires education of clinicians
Pearse A Keane,Eric J Topol
doi : 10.1016/S0140-6736(21)00722-4
PERSPECTIVES|DIGITAL MEDICINE| VOLUME 397, ISSUE 10281, P1254, APRIL 03, 2021
Joia Crear-Perry: collaborating for racial and reproductive justice
Udani Samarasekera
doi : 10.1016/S0140-6736(21)00723-6
PERSPECTIVES|PROFILE| VOLUME 397, ISSUE 10281, P1255, APRIL 03, 2021
Diabetes, race, and amputations
Richard M Mizelle Jr
doi : 10.1016/S0140-6736(21)00724-8
PERSPECTIVES|THE ART OF MEDICINE| VOLUME 397, ISSUE 10281, P1256-1257, APRIL 03, 2021
Stuart Saunders
Andrew Green
doi : 10.1016/S0140-6736(21)00725-X
OBITUARY| VOLUME 397, ISSUE 10281, P1258, APRIL 03, 2021
The UK Health and Care Bill: failure to address fundamental issues of coverage and funding
Michael Anderson,Emma Pitchforth,Alistair McGuire,Elias Mossialos
doi : 10.1016/S0140-6736(21)00525-0
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1259, APRIL 03, 2021
Missing again: US racial and ethnic data for COVID-19 vaccination
Nancy Krieger,Pamela D Waterman,Jarvis T Chen,Christian Testa,William P Hanage
doi : 10.1016/S0140-6736(21)00465-7
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1259-1260, APRIL 03, 2021
The medical right to repair: the right to save lives
Shuhan He,Debbie Lai,Jarone Lee
doi : 10.1016/S0140-6736(21)00445-1
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1260-1261, APRIL 03, 2021
Malnutrition risk in hospitalised COVID-19 patients receiving CPAP
Pete Turner,Hugh Montgomery,Mike Stroud,George Grimble,Trevor Smith
doi : 10.1016/S0140-6736(21)00447-5
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1261, APRIL 03, 2021
Free licensing of vaccines to end the COVID-19 crisis
Kayvan Bozorgmehr,Rosa Jahn,David Stuckler,Martin McKee
doi : 10.1016/S0140-6736(21)00467-0
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1261-1262, APRIL 03, 2021
Guidelines should not pool evidence from uncomplicated and severe COVID-19
Nicholas J White,Nathalie Strub-Wourgaft,Abul Faiz,Philippe J Guerin
doi : 10.1016/S0140-6736(21)00469-4
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1262-1263, APRIL 03, 2021
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
Salim S Abdool Karim
doi : 10.1016/S0140-6736(21)00468-2
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1263-1264, APRIL 03, 2021
Gender, race, and health workers in the COVID-19 pandemic
Gabriela Lotta,Michelle Fernandez,Denise Pimenta,Clare Wenham
doi : 10.1016/S0140-6736(21)00530-4
CORRESPONDENCE| VOLUME 397, ISSUE 10281, P1264, APRIL 03, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00726-1
DEPARTMENT OF ERROR| VOLUME 397, ISSUE 10281, P1264, APRIL 03, 2021
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study
Stephanie J Salyer,Justin Maeda,Senga Sembuche,Yenew Kebede,Akhona Tshangela,Mohamed Moussif,Chikwe Ihekweazu,Natalie Mayet,Ebba Abate,Ahmed Ogwell Ouma,John Nkengasong
doi : 10.1016/S0140-6736(21)00632-2
ARTICLES| VOLUME 397, ISSUE 10281, P1265-1275, APRIL 03, 2021
Although the first wave of the COVID-19 pandemic progressed more slowly in Africa than the rest of the world, by December, 2020, the second wave appeared to be much more aggressive with many more cases. To date, the pandemic situation in all 55 African Union (AU) Member States has not been comprehensively reviewed. We aimed to evaluate reported COVID-19 epidemiology data to better understand the pandemic's progression in Africa.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Shahin Lockman,Sean S Brummel,Lauren Ziemba,Lynda Stranix-Chibanda,Katie McCarthy,Anne Coletti,Patrick Jean-Philippe,Ben Johnston,Chelsea Krotje,Lee Fairlie,Risa M Hoffman,Paul E Sax,Sikhulile Moyo,Nahida Chakhtoura,Jeffrey SA Stringer,Gaerolwe Masheto,Violet Korutaro,Haseena Cassim,Blandina T Mmbaga,Esau Jo?o,Sherika Hanley,Lynette Purdue,Lewis B Holmes,Jeremiah D Momper,Roger L Shapiro,Navdeep K Thoofer,James F Rooney,Lisa M Frenkel,K Rivet Amico,Lameck Chinula,Judith Currieron behalf of the IMPAACT 2010/VESTED Study Team and Investigators
doi : 10.1016/S0140-6736(21)00314-7
ARTICLES| VOLUME 397, ISSUE 10281, P1276-1292, APRIL 03, 2021
Antiretroviral therapy (ART) during pregnancy is important for both maternal health and prevention of perinatal HIV-1 transmission; however adequate data on the safety and efficacy of different ART regimens that are likely to be used by pregnant women are scarce. In this trial we compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir, emtricitabine, and tenofovir alafenamide fumarate; dolutegravir, emtricitabine, and tenofovir disoproxil fumarate; and efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial
Stéphane Gaudry,David Hajage,Laurent Martin-Lefevre,Saïd Lebbah,Guillaume Louis,Sébastien Moschietto,Dimitri Titeca-Beauport,Béatrice La Combe,Bertrand Pons,Nicolas de Prost,Sébastien Besset,Alain Combes,Adrien Robine,Marion Beuzelin,Julio Badie,Guillaume Chevrel,Julien Bohé,Elisabeth Coupez,Nicolas Chudeau,Saber Barbar,Christophe Vinsonneau,Jean-Marie Forel,Didier Thevenin,Eric Boulet,Karim Lakhal,Nadia Aissaoui,Steven Grange,Marc Leone,Guillaume Lacave,Saad Nseir,Florent Poirson,Julien Mayaux,Karim Asehnoune,Guillaume Geri,Kada Klouche,Guillaume Thiery,Laurent Argaud,Bertrand Rozec,Cyril Cadoz,Pascal Andreu,Jean Reignier,Jean-Damien Ricard,Jean-Pierre Quenot,Didier Dreyfuss
doi : 10.1016/S0140-6736(21)00350-0
ARTICLES| VOLUME 397, ISSUE 10281, P1293-1300, APRIL 03, 2021
Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy.
Anterior uveitis in paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2
Justin E R E Wong Chung,? Engin,T F W Wolfs,T J C Renson,J H de Boer
doi : 10.1016/S0140-6736(21)00579-1
CLINICAL PICTURE| VOLUME 397, ISSUE 10281, E10, APRIL 03, 2021
Psoriasis
Christopher E M Griffiths,April W Armstrong,Johann E Gudjonsson,Jonathan N W N Barker
doi : 10.1016/S0140-6736(20)32549-6
SEMINAR| VOLUME 397, ISSUE 10281, P1301-1315, APRIL 03, 2021
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society. It is associated with several important medical conditions, including depression, psoriatic arthritis, and cardiometabolic syndrome. Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption. There are several phenotypes and research has separated pustular from chronic plaque forms. Immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis. Immune targeting of these cytokines and of TNF? by biological therapies has revolutionised the care of severe chronic plaque disease. Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.
Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions
Philippe Van de Perre,Ameena Goga,Nobubelo Ngandu,Nicolas Nagot,Dhayendre Moodley,Rachel King,Jean-Pierre Molès,Beatriz Mosqueira,Witness Chirinda,Gabriella Scarlatti,Thorkild Tyllesk?r,François Dabis,Glenda Gray
doi : 10.1016/S0140-6736(21)00570-5
HEALTH POLICY| VOLUME 397, ISSUE 10281, P1316-1324, APRIL 03, 2021
The rate of mother-to-child transmission (MTCT) of HIV from breastfeeding is increasing relative to other causes of MTCT. Early effective preconception and antenatal antiretroviral therapy (ART) reduces intrauterine and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untreated maternal HIV, and suboptimal postnatal maternal ART adherence increase the risk of MTCT through breastfeeding. Although the absolute number of cases of MTCT acquired through breastfeeding is decreasing, the rate of decrease is less than the decrease in intrauterine and intrapartum MTCT. Unless current strategies are universally applied, they might not be sufficient to eliminate MTCT due to breastfeeding. Urgent action is needed to evaluate and implement additional preventive biomedical strategies in high HIV prevalence and incidence settings to eliminate MTCT from breastfeeding. Preventive strategies include: pre-exposure prophylaxis in breastfeeding women who have an increased risk of acquiring HIV; postnatal reinforcement strategies, such as maternal retesting for HIV, maternal care reinforcement, and prophylaxis in infants exposed to HIV via breastmilk; and active (vaccine) or passive immunoprophylaxis with long-acting broadly neutralising antibodies.
